Sage Therapeutics Inc. (SAGE) announced Tuesday morning that its Phase 2 clinical trial of SAGE-547 for the treatment of severe postpartum depression achieved the primary endpoint of a significant reduction in the HAM-D score compared to placebo at 60 hours.
from RTT - Before the Bell http://ift.tt/29xQdKI
via IFTTT
No comments:
Post a Comment